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Abstract
Background: Autoantibodies, in particular those against aquaporin-4 and myelin-oligodendrocyte glycoprotein
(MOG), aid as biomarkers in the differential diagnosis of demyelination. Here, we report on discovery of
autoantibodies against flotillin in patients with multiple sclerosis (MS).
Methods: The target antigen was identified by histo-immunoprecipitation using the patients’ sera and cryosections of
rat or pig cerebellum combined with mass spectrometrical analysis. Correct identification was ascertained by indirect
immunofluorescence and neutralization tests using the target antigens recombinantly expressed in HEK293 cells.
Results: Serum and CSF of the index patient produced a fine-granular IgG indirect immunofluorescence staining of the
hippocampal and cerebellar molecular layers. Flotillin-1 and flotillin-2 were identified as target autoantigens. They
also reacted with recombinant human flotillin-1/2 co-expressed in HEK293 cells, but not with the individual flotillins in
fixed- and live-cell assays. Moreover, neutralization using flotillin-1/2, but not the single flotillins, abolished the tissue
reactivity of patient serum. Screening of 521 patients, for whom anti-aquaporin-4 testing was requested and negative,
revealed 8 additional patients with anti-flotillin-1/2 autoantibodies. All eight were negative for anti-MOG. Six
patients ex post fulfilled the revised McDonald criteria for MS. Vice versa, screening of 538 MS sera revealed
anti-flotillin-1/2 autoantibodies in eight patients. The autoantibodies were not found in a cohort of 67 patients
with other neural autoantibody-associated syndromes and in 444 healthy blood donors.
Conclusions: Autoantibodies against the flotillin-1/2 heterocomplex, a peripheral membrane protein that is involved
in axon outgrowth and regeneration of the optic nerve, are present in 1–2% of patients with bona fide MS.
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Background
Several immune-mediated inflammatory central nervous
system (CNS) disorders are characterized by the presence
of autoantibodies against components of neural tissues
[1]. Moreover, a significant number of autoantibodies with
pathogenic potential, e.g., directed against aquaporin-4,
have been described [2–7]. Autoantibodies against
aquaporin-4 (AQP4) cause inflammation in the CNS and
can be regarded as pathognomonic for neuromyelitis
optica spectrum disorder (NMOSD) [2, 8–10]. Lead
symptoms are uni- or bilateral optic neuritis (ON)
together with longitudinal extensive transverse myelitis
[11]. ON and transverse myelitis are also frequent initial
symptoms in multiple sclerosis (MS). Most MS patients
develop ON at least once during the disease course [12],
and conversely, both children and adults with ON have an
elevated risk of developing MS [13, 14]. Generally,
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neuroimaging and laboratory testing help to diagnose and
differentiate MS, NMOSD, and other forms of central
demyelination [10]. However, intrathecal immunoglobulin
synthesis and oligoclonal bands in the CSF, frequently
detected in patients with MS, are not disease-specific.
Searching for anti-AQP4 has therefore become an import-
ant step in the diagnostic work-up of patients under suspi-
cion of having a central demyelinating disease. Broad
screening for multiple autoantibodies is justified at this
stage because they can be linked to phenotypically diffuse
neurological syndromes, especially in early disease stages.
Conclusively, ex ante unexpected findings are frequent in
the serological laboratory.
Here, we report on autoantibodies against the flotillin-
1/2 complex detected in patients referred for anti-AQP4
testing, most of whom turned out to suffer from bona
fide multiple sclerosis presenting with ON. Flotillin-1
and flotillin-2 (reggie-2 and reggie-1) are homologous
scaffolding proteins of lipid raft microdomains with a
molecular mass of 47 kDa [15, 16]. They are highly
conserved and ubiquitously expressed [17]. Membrane
association of flotillins depends amongst other factors
on palmitoylation at Cys34 of flotillin-1 [18, 19] and
Cys4, Cys19, and Cys20 of flotillin-2 [20, 21]. The flotil-
lin proteins form hetero-oligomeric complexes and were
originally named reggies due to their upregulation in
regenerating axons of goldfish retinal ganglion cells after
lesion of the optic nerve [22]. Furthermore, they play an
important role in cell proliferation, tumor progression,
neurodegenerative diseases, and signaling in T cells.
Flotillin microdomains form flotillin cap at one pole of
T cells regulating recruitment of signaling molecules to
the cap which is important for T cell activation [15].
Methods
Patients were analyzed as part of their diagnostic work-
up based on the suspicion of a neuroinflammatory
disease by a broad screening for autoantibodies. Serum
and CSF samples were initially investigated on the
assumption of an autoimmune disorder of the CNS in
the accredited Clinical Immunological Laboratory in
Lübeck by indirect immunofluorescence assay (IFA)
using a combination of brain tissue cryosections and
HEK293 cells expressing established neural autoantigens
between May 2012 and September 2015.
The six patients revealed in the initial screening were
diagnosed and treated at the Departments of Neurology
of the contributing Medical Centers and Hospitals. All
patients were referred for serology as part of their diag-
nostic work-up based on the clinical differential diagno-
sis between MS and NMOSD mostly due to clinical
presentation with prominent ON by a broad screening
for autoantibodies. The index patient (P1) gave written
informed consent for using her serum and CSF samples
for autoantigen identification. All six patients for whom
detailed data are reported consented to the serological
analysis of their samples and the subsequent evaluation
of their medical records.
Control collectives included 538 serum samples from
random patients with pre-diagnosed MS, 444 healthy
blood donors, and 67 patients with defined autoantibody-
associated neurological syndromes (5x anti-NMDAR, 5x
anti-Hu, 2x anti-Hu/anti-Ri, 3x anti-Yo, 2x anti-Yo/
anti-Ri, 3x anti-Ri, 38x anti-AQP4, 5x anti-LGI1, 4x
anti-CASPR2).
Reagents were obtained from Euroimmun (Lübeck,
Germany) or Merck (Darmstadt, Germany) or Sigma-
Aldrich (Heidelberg, Germany) if not specified otherwise.
Histo-immunoprecipitation and identification of the
antigen
The cerebellum from rat or pig was dissected and
shock-frozen in −160 °C isopentane. The tissue was then
cryosected (4 μm) with a SM2000R microtome (Leica
Microsystems, Nussloch, Germany), placed on glass
slides, dried, and stored at −196 °C. For histo-
immunoprecipitation (HIP), the slides were incubated
with the patient’s serum (diluted 1:100) at 4 °C for 3 h
followed by three washing steps with PBS, 0.2% (w/v)
Tween-20 (IFA buffer). The tissue was then extracted
with solubilization buffer (100 mmol/l tris-HCl pH 7.4,
150 mmol/l sodium chloride, 2.5 mmol/l EDTA, 0.5%
(w/v) deoxycholate, 1% (w/v) Triton X-100 containing
protease inhibitors) at 4 °C for 1 h. The resulting sus-
pension was homogenized and centrifuged at 16,000×g
at 4 °C for 15 min. Immunocomplexes were precipitated
from the clear supernatant with Protein G Dynabeads
(ThermoFisher Scientific, Dreieich, Germany) at 4 °C
overnight, washed three times with solubilization buffer,
and eluted with NuPAGE LDS Sample Buffer (Thermo
Fisher Scientific, Dreieich, Germany) at 70 °C for
10 min. The eluates were analyzed by SDS-PAGE and
mass spectrometry or Western blot.
Indirect immunofluorescence assay
Slides with biochip mosaic including brain tissue cryo-
sections (rat hippocampus and rat, pig, and primate
cerebellum) and HEK293 cells expressing wild-type and
mutated flotillin-1 and flotillin-2 as well as 30 recom-
binant brain antigens were used for IFA. Each mosaic
was incubated with 30 μl of sample diluted in PBS,
0.2% Tween-20 (IFA buffer) at room temperature for
30 min; flushed with IFA buffer; and immersed in IFA
buffer for 5 min. Subsequently, polyclonal goat anti-
human pan-IgG (Euroimmun, Lübeck, Germany) or
monoclonal murine anti-human IgG1, IgG2, IgG3, or
IgG4 (Sigma-Aldrich, Heidelberg, Germany), each la-
beled with fluorescein isothiocyanate (FITC) or Alexa
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Fluor 488, were incubated at room temperature for
30 min. The slides were then washed again; embedded
in PBS-buffered, DABCO-containing glycerol (approxi-
mately 10 μl per mosaic); and examined by two inde-
pendent observers using an EUROStar microscope
(Euroimmun, Lübeck, Germany) and a laser scanning
microscope (LSM700, Zeiss, Jena, Germany). Positive
and negative controls were included. Samples were
categorized based on tissue patterns and fluorescence
intensity of transfected cells in direct comparison with
non-transfected cells and control samples. Endpoint
titers refer to the highest dilution showing visible fluor-
escence. Live-cell IFA with primary hippocampal neu-
rons or transfected HEK293 cells was conducted as
described by Dalmau et al. [3].
Polyclonal rabbit antibodies against flotillin-1 and
flotillin-2 (both Sigma-Aldrich, Heidelberg, Germany;
dilution 1:250), respectively, were used in some experi-
ments in the first step followed by incubation with anti-
rabbit IgG-Cy3 (Jackson Research, Suffolk, UK). Cell
nuclei were visualized by DNA staining with TO-PRO-3
iodide (ThermoFisher Scientific, Dreieich, Germany;
dilution 1:2000). Recombinant antigens were mixed with
diluted serum sample 1 h at room temperature prior to
IFA as described in Stöcker et al. for neutralization
experiments [23].
See Additional file 1 for further details.
Results
Characterization of the patient’s autoantibodies
The IFA analysis of the index patient’s (P1) serum and
CSF revealed a fine-granular IgG staining of the mo-
lecular layer on the rat hippocampus as well as on the
rat and primate cerebella (Fig. 1, Additional file 1: Figure
e-5). The hippocampal inner molecular layer showed a
more intense staining than the outer molecular layer.
Serum and CSF titers were 1:320 and 1:32, respectively,
and the antibodies were of subclass IgG1, exclusively
(see details in Table 1, Additional file 1: Figure e-5).
Further monospecific analyses revealed no specific re-
activity applying 30 different neural autoantigens recom-
binantly expressed in HEK293 cells: Hu, Yo, Ri, CV2,
SOX1, PNMA1, PNMA2, ITPR1, Homer 3, CARP VIII,
ARHGAP26, ZIC4, DNER/Tr, GAD65, GAD67, amphi-
physin, recoverin, GABA B receptor, glycine receptor,
DPPX, glutamate receptors (types NMDA, AMPA,
mGluR1, mGluR5), LGI1, CASPR2, AQP4 (M1 and
M23), MOG, and ATP1A3.
Identification of flotillin as the target autoantigen
Immunocomplexes precipitated with the patient’s
serum from the rat cerebellum contained proteins of
approximately 50 kDa, as detected by SDS-PAGE,
which were absent in equally prepared controls
(Fig. 2A). Using MALDI-TOF, the 50-kDa proteins
were identified as flotillin-1 and flotillin-2 from Rattus
norvegicus (UNIPROT acc. # Q9Z1E1, Q9Z2S9) and
Sus scrofa (#Q767L6, I3LFS8), respectively.
Western blot analysis of the immunoprecipitates ex-
hibited a strong reaction at 50 kDa applying polyclonal
rabbit anti-flotillin-1 and anti-flotillin-2 antibodies, re-
spectively (Fig. 2A and Additional file 1: Figure e-1A).
When used in IFA, the anti-flotillin-1 and anti-flotillin-2
antibodies produced fluorescence patterns on rat hippo-
campus as well as on rat and primate cerebella compar-
able to those generated by the patient samples (Fig. 2B
and Additional file 1: Figure e-1B).
As a proof of correct antigen identification, the pa-
tient’s samples were then tested by IFA using recombin-
ant HEK293 cells which expressed either flotillin-1,
flotillin-2, or both proteins (Fig. 3A). Serum (Additional
file 1: Figure e-3) and CSF (Additional file 1: Figure e-5)
reacted with the cells co-expressing flotillin-1 and
flotillin-2 after acetone fixation and in live-cell IFA
(Additional file 1: Figure e-4) but not with those ex-
pressing individual flotillin-1 or flotillin-2. Endpoint
titers were higher with the recombinant substrates than
titers determined on tissue. Mock transfection did not
result in any antibody binding.
The congruence of the autoantibody target and
flotillin-1/2 was further demonstrated by the proof of a
dose-dependent neutralization of antibody binding to
brain tissue: An incubation of the patient’s samples with
HEK293 lysate containing co-expressed flotillin-1 and
flotillin-2 abolished the positive IFT reaction which did
not happen if separately expressed flotillin-1 or flotillin-
2 or lysates from mock-transfected HEK293 were added
to the patient’s samples (Fig. 3B).
Surface localization of autoantibody-binding recombinant
flotillin-1/2
To study the membrane association of flotillins, acylation-
deficient mutants were expressed in HEK293 cells. For this
purpose, Cys5 and Cys17 of flotillin-1 and Cys4, Cys19, and
Cys20 of flotillin-2 were replaced by serine [A: flotillin-1
wild-type + flotillin-2 wild-type; B: flotillin-1 wild-type +
flotillin-2 (C4S, C19S, C20S); C: flotillin-1 (C5S, C17S) +
flotillin-2 wild-type; D: flotillin-1 (C5S, C17S) + flotillin-2
(C4S, C19S, C20S)] (Additional file 1: Figure e-2). Using
non-permeabilized HEK293 cells in a live cell-based assay,
the patient serum and the antibodies against flotillin-1 and
flotillin-2 only displayed reactions with the wild-type
flotillin-1/2. Co-expression of acylation-deficient flotillin-1
(C5S, C17S) and flotillin-2 (C4S, C19S, C20S) impaired anti-
body binding to the flotillins and abolished the reactivity of
patient serum and polyclonal antibodies, indicating that flo-
tillins are not trafficked to the cellular surface without the
attachment of fatty acids (Additional file 1: Figure e-4).
Hahn et al. Journal of Neuroinflammation  (2017) 14:123 Page 3 of 10
Estimation of anti-flotillin-1/2 autoantibody prevalence
Anti-flotillin-1/2 status was determined in 521 samples re-
ferred for anti-AQP4 testing due to suspected autoimmune
inflammatory CNS disorder (1) which had been found
to be anti-AQP4-negative; (2) for which a general
broad neural autoantibody screening, including the
aforementioned parameters, had been conducted in the
Clinical Immunological Laboratory, Lübeck (Germany);
and (3) for which a neural tissue-reactive IgG autoanti-
body without known antigen specificity had been
reported. Serum anti-flotillin-1/2 was detected in nine pa-
tients with titers of up to 1:10,000. For five of these
patients, medical records were available (P2–P6 in
Table 1). Patients P2, P3, and P5 also showed anti-flotillin-
1/2 in CSF (titers 1:3.2, 1:100, and 1:1000). For P4 and P6,
CSF was not available. Additional follow-up sera of the
patients were analyzed when available and showed that
the anti-flotillin-1/2 titers of P1, P2, and P4 were un-
altered over a period of 18, 24, and 72 months, respect-
ively, despite initiation of disease-modifying treatment
Fig. 1 Immunofluorescence staining of central nervous tissues. Cryosections of rat hippocampus (A) and cerebellum (B) as well as primate
cerebellum (C) were incubated with patient serum (A–C) or with control serum (A′–C′) (A–C1, A′–C′ 1:100, A–C2, C3 1:50) in the first step and with
Alexa Fluor 488-labeled goat anti-human IgG in the second step (green). Nuclei were counterstained by incubation with TO-PRO-3 iodide (blue). A
fine-granular staining of the stratum moleculare (sm) was obtained. On the hippocampus, the sm internum was stained more intensely than the
sm externum. Scale bar: 100 μm (A–C1, A′–C′), 20 μm (A–C2, C3). h hilus, sm stratum moleculare, smi stratum moleculare internum, sme stratum
moleculare externum, sg stratum granulosum, sp stratum purkinjense
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for MS (interferon-β or natalizumab). The serum of P5
showed a reduction from 1:1000 to 1:320 7 weeks after
plasma exchange, to which the patient had responded
well clinically.
Screening of 538 serum samples from pre-diagnosed
MS patients revealed anti-flotillin-1/2 autoantibodies in
eight further patients (Additional file 1: Table e-2). All
eight patient samples did not contain antibodies against
AQP4 and MOG; however, screening of the remaining
530 samples uncovered 3 anti-AQP4- and 10 anti-
MOG-positive sera in patients diagnosed with MS. Sera
from 67 patients with various neural autoantibodies,
Fig. 2 Histo-immunoprecipitation and antigen identification. Cryosections of rat or pig cerebellum were incubated with the serum (1:100),
washed in PBS, and solubilized using detergents. The solution was incubated with protein-G-coated magnetic beads. The immunocomplexes
were eluted by SDS and subjected to SDS-PAGE analysis and Western blot. A Western blot after incubation with anti-flotillin-2 (A1) and enzymatic
visualization of antibody binding. Staining of SDS polyacrylamide gel with colloidal Coomassie (A2). Lane 1: molecular mass (kDa) marker; lanes
2–8: histo-immunoprecipitates of patient sera from rat cerebellum; lanes 9–15: histo-immunoprecipitates of control samples. The arrow indicates
the position of the immunoprecipitated antigen 50 kDa while dotted arrows indicate the position of IgG heavy and light chain at 52 and 27 kDa,
respectively. PS patient sample, CS control sample. B Immunofluorescence staining of rat hippocampus (B1) and cerebellum (B2) and primate
cerebellum (B3) tissue sections with patient serum (green, 1–3) and anti-flotillin-2 antibody (red, 1′–3′). The merged images show localization of
the reactivity in the same region including the more intense staining of the sm internum on the hippocampus (1″–3″). Scale bar: 50 μm (large
images), 100 μm (inserts). PS patient serum, CS control serum, h hilus, sg stratum granulosum, sm stratum moleculare, smi stratum moleculare
internum, sme stratum moleculare externum, sp stratum purkinjense
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including 38 with anti-AQP4 (titers up to 1:3200), and
from 444 healthy participants (blood donors of both
sexes, 18–67 years) were analyzed as specificity controls.
None of the sera reacted with HEK293-flotillin-1,
HEK293-flotillin-2, and HEK293-flotillin-1/2.
Patient characteristics
In summary, 13 of the 14 anti-flotillin-1/2-positive
patients for whom medical records could be evaluated
had relapses, radiological signs of disseminated demye-
lination, and no evidence for a disorder other than MS,
ex post fulfilling the revised diagnostic criteria of
relapsing-remitting MS [24]. Providing direct evidence
for the inflammatory nature of the disease, CSF analysis
had revealed mild pleocytosis and/or CSF-specific
oligoclonal band (OCB) in all patients. One patient had
been diagnosed with secondary progressive MS. Thirteen
(93%) patients were female. Nine (64%) patients had a
history of optic neuritis. None of the patients displayed
anti-AQP4 or anti-MOG antibodies. Where available
(P1, P2, P3, and P5), CSF was found to harbor anti-
flotillin-1/2. Specific antibody indices >4 indicative for
intrathecal anti-flotillin-1/2 synthesis, as suggested by
Reiber et al. for IFA analysis [25], were calculated for
P1, P3, and P5. See Table 1 and Additional file 1 for
more details.
Discussion
We report on IgG autoantibodies against the flotillin-1/2
complex. The autoantibodies were revealed during the
Fig. 3 Immunofluorescence staining of recombinant flotillin and the neutralization of antibody reaction on tissue. A Immunofluorescence analysis
of transfected HEK293 cells. Acetone-fixed recombinant HEK293 cells expressing flotillin-1 (1), flotillin-2 (2), flotillin-1 and flotillin-2 (3) or a mock-
transfected control (4) were incubated with patient serum (1–4) or with control serum (1′–4′) (both 1:100). Cell nuclei were counterstained with
TO-PRO-3 iodide (blue). Only HEK293-flotillin-1/2 cells reacted with the samples (green). Scale bar: 50 μm. B Neutralization of immunofluorescence
reaction on neuronal tissues. Serum was pre-incubated with extracts of HEK293 cells transfected with empty control vector (1–4) or with the
plasmid harboring flotillin-1/2 cDNA (1′–4′). The extract containing flotillin-1/2 greatly reduced or abolished the immune reaction of the serum on
rat hippocampus (1′) and cerebellum (2′), primate cerebellum (3′), and HEK293-flotillin-1/2 (4′). The control extracts had no effect (1–4). Nuclei were
counterstained by incubation with TO-PRO-3 iodide (blue). Scale bar: 50 μm. PS patient serum, CS control serum, sg stratum granulosum, sm
stratum moleculare, sp stratum purkinjense
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serological work-up of patients referred for anti-AQP4
testing as an unexpected finding. The patients’ sera and
CSF reacted with cryosections of neural tissue but not
with any of 30 previously established brain autoantigens
in fixed recombinant cell-based IFA, including AQP4
and MOG. Histo-immunoprecipitation combined with
mass spectrometry and recombinant expression identi-
fied the heterocomplex as the target antigen. All six
index patients for whom medical records could be evalu-
ated presented with a history of encephalomyelitis and/
or inflammation of the optic nerve(s). Ex post, all pa-
tients fulfilled the revised diagnostic criteria for MS
which prompted the search for anti-flotillin-1/2 in a
cohort of 538 pre-diagnosed MS patients that revealed
another 8 patients bearing the autoantibodies. Import-
antly, the antibodies were not detected in >500 controls.
Flotillin-1 and Flotillin-2 (synonyms: reggie-2 and
reggie-1) were originally described to be upregulated in
regenerating axons of goldfish retinal ganglion cells after
traumatic injury of the optic nerve [22]. They are evolu-
tionary well conserved in many eukaryotes including
mammals [26, 27]. Human and rat flotillin-1 share 98%
identity whereas the homology of human and rat/pig
flotillin-2 is even 99%. In vertebrates, both proteins are
ubiquitously expressed and abundant in striated muscle,
adipose, lung tissue, and brain [15, 28]. On the cellular
level, flotillins have been reported to be located in lipid
rafts [28]. Functionally, flotillins have been shown to be in-
volved in endocytosis, cell signaling, clustering of the amyl-
oid precursor protein (APP) and amyloidogenic processing
in neurons. Expression in glial cells has not been reported
thus far. Moreover, artificial induction of flotillin expression
in retinal ganglion cells in vivo leads to regeneration of sub-
sequently crushed optic nerves in rats, thereby overcoming
factors that inhibit this process in mammals under wild-
type circumstances [27]. SiRNA-mediated downregulation
of flotillin-2 affects neuronal differentiation and process
formation in hippocampal neurons [29].
Despite of the abundant data on the individual flotillin
proteins, information on expression, distribution, and func-
tion of flotillin-1 and flotillin-2 homo- and heterocomplexes
is limited. Our own data indicate the presence of re-
combinant wild-type flotillin-1/2 on the surface of HEK293
cells whereas acylation-deficient but autoantibody-binding
flotillin-1/2 is retained within the cells. Given that authentic
flotillin-1/2 heterocomplexes were temporarily present on
cell surfaces of neural cells in vivo or on signal-transducing
exosomes [30], the autoantibodies could bear pathogenic
potential. Furthermore, the antibodies univocally belong to
the complement-activating IgG1 subclass, seem to be pro-
duced within the CNS, and remained detectable over the
entire disease course in all three patients with long-term
follow-up, and P5 favorably responded to plasma exchange.
These facts are compatible with a role of anti-flotillin-1/2
in the inflammatory process. However, an involvement of
anti-flotillin-1/2 and/or the flotillin proteins in MS patho-
genesis is only speculative based on our data. The anti-
bodies may as well be a result of an overshooting immune
response during the inflammatory process and represent an
immunological epiphenomenon.
In the six anti-flotillin-1/2-positive patients in whom the
antibody was found prospectively and for whom we could
evaluate medical records, testing for anti-AQP4 and anti-
MOG was initially requested based on clinically assessed
NMOSD core characteristics like myelitis and/or optic
neuritis [10]. However, none met the latest international
consensus criteria for NMOSD and all demonstrated “red
flag” criteria according to that consensus, strongly sug-
gesting another form of encephalomyelitis [10]. Neu-
roimaging; laboratory features, including the presence of
typical MS lesions on brain MRI and of CSF-restricted
oligoclonal bands; and fulfillment of the revised diagnostic
criteria indicated MS in all patients [24]. Based on our
prospective approach regarding the disease phenotype and
the absence of anti-flotillin-1/2 in the controls, as well as
based on the retrospective confirmation in a large cohort
of pre-diagnosed MS patients, the flotillin-1/2 heterocom-
plex seems to be a B cell autoantigen in a subset of about
1–2% of MS patients.
Conclusions
Taken together, the compiled data indicate flotillin-1/2
heterocomplex as a target antigen of autoantibodies in a
subset of patients with bona fide MS. More precise data
regarding the time point at which anti-flotillin-1/2 is in-
duced, and the phenotype relation and the prevalence
have to be assembled in large cohorts of patients with
inflammatory demyelinating CNS disorders including
CIS; acute disseminated encephalomyelitis; NMOSD,
each with and without ON; and isolated ON in order to
discern the diagnostic, therapeutic, and prognostic value
of these autoantibodies. Furthermore, these future data
will help to elucidate the pathological relevance and
functional relationship of flotillin antibodies.
Additional file
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